But in non-small cell lung cancer, it was reported that NRF2 promoter activity and its mRNA levels were markedly suppressed by wild-type p53, but not by mutant p53; while mutant p53 could upregulate NRF2 expression at the transcriptional level, thereby conferring cisplatin resistance [15]. This evidence concerns the gene TP53 and non-small cell lung carcinoma.